SWOG clinical trial number
SWOG-8005

Evaluation of Dihydroxyanthracenedione (DHAD) in Refractory Malignant Lymphomas

Closed
Phase
Abbreviated Title
Evaluation of Dihydroxyanthracenedione (DHAD) in Refractory Malignant Lymphomas
Activated
07/02/1980
Closed
05/10/1982

Research committees

Lymphoma

Publication Information Expand/Collapse

1984

Mitoxantrone in refractory NonHodgkin's lymphoma: A Southwest Oncology Group study

CA Coltman Jr;TM Coltman;SP Balcerzak;FS Morrison;DD Von Hoff Semin Oncol 11(3 Suppl 1):50-53

Mitoxantrone in refractory non-Hodgkin's lymphoma

CA Coltman Jr;TM Coltman;SP Balcerzak;FS Morrison;DD Von Hoff 2nd International Conference on Malignant Lymphoma (Swiss League Against Cancer and Swiss Group for Clinical Cancer Research Lugano Switzerland June 13-16 1984) 98

1983

Mitoxantrone hydrochloride (NSC-301739) in lymphoma. A Southwest Oncology Group study

CA Coltman Jr;TM McDaniel;SP Balcerzak;FS Morrison;DD Von Hoff Investigational New Drugs 1:065-070

Mitoxantrone hydrochloride in lymphoma

CA Coltman Jr;TM McDaniel;SP Balcerzak;FS Morrison;DD Von Hoff In: 13th International Congress of Chemotherapy (Vienna, August 28-Sepember 2, 1983). KH Spitzy, K Karrer, eds. Symposium Mitoxantrone 212:52-55

Mitoxantrone hydrochloride in lymphoma

CA Coltman Jr;TM McDaniel;SP Balcerzak;FS Morrison;DD Von Hoff Cancer Treat Rev 10(Suppl B):73-76

Mitoxantrone hydrochloride in hematologic malignancies: Southwest Oncology Group Phase II studies.

CA Coltman Jr;JH Saiki;FJ Panettiere;SP Balcerzak;RL Stephens;FS Morrison;DO Dixon;DD Von Hoff In: 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (Brussels, October 15-17, 1981) M Rozencweig, DD Von Hoff, MJ Staquet, eds. New Anticancer Drugs: Mitoxantrone and Bisantrene. New York: Raven Press 115-124.

1981

Mitoxantrone Hydrochloride (NSC-30179) in hematologic malignancies

CA Coltman Jr;JH Saiki;FJ Panettiere;SP Balcerzak;RL Stephens;FS Morrison;DO Dixon;DD Von Hoff 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (Brussels)

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
11%
Open
Phase